Moreover, in vitro and in vivo studies revealed potential advantages of co-treatment with menin inhibitors such as SNDX-50469 (VTP50469), revumenib (SNDX-5613), or ziftomenib (KO-539) alongside the BCL2 inhibitor venetoclax, FLT3 inhibitors, or immunoproteasome-targeting agents for KMT2A-rearranged and NPM1-mutated leukemia, regardless of the FLT3 and TP53 mutation status [27,28,29,30,31]. The gene discussed is KMT2A; the disease is leukemia.